Oral Biologics Advantage Target health systems and biopharma buyers seeking non-invasive biologic delivery. Fzata’s BioPYM platform offers oral, non-refrigerated, needle-free biologics with potential to expand patient access, positioning it for partnerships with manufacturers, contract development and manufacturing organizations (CDMOs), and payer-focused value propositions.

BioPYM Platform Identify opportunities with collaborators interested in live biologics delivery in pill form. The Live Biologics In A Pill platform represents a frontier area that could align with gastrointestinal specialty clinics, academic partnerships, and biotech players seeking novel oral therapeutics to diversify their portfolios.

Geographic Focus Leverage location in Halethorpe/Greater BioHealth Capital Region to engage regional life sciences networks, state innovation programs, and regional pharma clusters for pilots, co-development grants, and regional procurement opportunities.

Recognition & Funding Utilize the 2022 Mid-Atlantic Innovation Celebration award and current revenue/funding signals to approach potential investors, strategic acquirers, and grant programs as credibility anchors in outreach and partnership pitches.

Growth Readiness Position Fzata as a scalable partner for larger pharma and CDMOs given its small team but growing platform narrative. Explore alliance opportunities for manufacturing, regulatory support, and commercialization pathways to accelerate adoption of oral biologics across GI and metabolic indications.